AssesSment of Early deteCtion basEd oN liquiD Biopsy in Intracranial Tumors
Recruiting
- Conditions
- Intracranial Tumors
- Interventions
- Device: early detection test
- Registration Number
- NCT05679089
- Lead Sponsor
- Zhujiang Hospital
- Brief Summary
ASCEND-BRAIN is a prospective, observational study aimed at early-detection of intracranial tumors by combined assays of cfDNA methylation and other biomarkers. The study will enroll approximately 358 participants including intracranial malignant tumors, patients with benign disorders of central nervous system and healthy participants.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- All
- Target Recruitment
- 358
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description Cancer Arm early detection test Participants with newly diagnosed intracranial malignant tumors, from whom blood samples will be collected. Benign Arm early detection test Participants with newly diagnosed benign central nervous system disorders, from whom blood samples will be collected. Healthy arm early detection test Participants without known presence of malignancies or certain benign diseases, from whom blood samples will be collected.
- Primary Outcome Measures
Name Time Method The sensitivity and specificity of a cfDNA methylation-based early detection model for intracranial tumors. 12 months
- Secondary Outcome Measures
Name Time Method The sensitivity and specificity of a cfDNA methylation-based early detection model for intracranial tumors of different grades(WHO I-IV) and mutant subtypes(IDH mutant/wild type). 12 months
Trial Locations
- Locations (1)
Zhujiang Hospital
🇨🇳Guangzhou, Guangdong, China